(ERAS) Erasca - NASDAQ
Sector: Healthcare | Industry: Biotechnology | Exchange: NASDAQ (USA) | Market Cap: 4.192m USD | Total Return: 821.7% in 12m
Avg Turnover: 61.7M
Qual. Beats: -1
Qual. Beats: 0
Warnings
Interest Coverage Ratio -0.9 is critical
Altman Z'' -0.17 < 1.0 - financial distress zone
Tailwinds
Rs Leader, Idiosyncratic Leader, Tailwind
Erasca, Inc. is a San Diego-based clinical-stage biotechnology company specializing in precision oncology. The firm focuses on the RAS/MAPK pathway, a frequent driver of oncogenesis that has historically been difficult to target with conventional small-molecule therapies. Its pipeline includes molecular glues, pan-KRAS inhibitors, and biparatopic antibodies designed to treat solid tumors with specific genetic mutations.
The company operates through a collaborative business model, utilizing licensing agreements with entities such as Novartis Pharma AG and NiKang Therapeutics to co-develop and commercialize its therapeutic candidates. In the biotechnology sector, this strategy allows clinical-stage firms to mitigate high R&D costs and leverage the manufacturing infrastructure of established pharmaceutical partners. Investors may find additional insights on these types of clinical partnerships by exploring ValueRay.
Erasca’s primary candidates, including ERAS-0015 and ERAS-4001, are currently undergoing evaluation for efficacy in RAS-mutated solid tumors. The company maintains clinical trial collaborations with Tango Therapeutics to support the development of its pan-RAS molecular glue program.
- Clinical trial data readouts for pan-RAS molecular glue ERAS-0015
- Pipeline prioritization and cash runway extension through strategic asset licensing
- Competitive positioning against established KRAS inhibitors in solid tumor markets
- Regulatory milestones for naporafenib combination therapies in RAS-mutated cancers
| Net Income: error (cannot be calculated; needs Net Income TTM and Revenue TTM) |
| FCF/TA: -0.54 > 0.02 and ΔFCF/TA -26.66 > 1.0 |
| NWC/Revenue: error (cannot be calculated; needs Current Assets/Liabilities and Revenue current+prev) |
| CFO/TA -0.20 > 3% & CFO -91.3m > Net Income -277.0m |
| Net Debt/EBITDA: error (EBITDA <= 0) |
| Current Ratio: 9.52 > 1.5 & < 3 |
| Outstanding Shares: last quarter (304.3m) vs 12m ago 7.43% < -2% |
| Gross Margin: error (current vs previous; cannot be calculated due to missing/invalid data or negative margin) |
| Asset Turnover: 0.0% > 50% (prev 0.89%; Δ -0.89% > 0%) |
| Interest Coverage Ratio: -0.91 > 6 (EBIT TTM -131.8m / Interest Expense TTM 145.3m) |
| A: 0.49 (Total Current Assets 253.8m - Total Current Liabilities 26.7m) / Total Assets 461.2m |
| B: -2.33 (Retained Earnings -1.08b / Total Assets 461.2m) |
| C: -0.28 (EBIT TTM -131.8m / Avg Total Assets 466.2m) |
| D: 5.81 (Book Value of Equity 393.5m / Total Liabilities 67.7m) |
| Altman-Z'' = -0.17 = B |
As of June 12, 2026, the stock is trading at USD 14.01 with a total of 5,687,459 shares traded.
Over the past week, the price has changed by +5.58%,
over one month by +34.20%,
over three months by -9.61% and
over the past year by +821.71%.
Erasca has received a consensus analysts rating of 4.63. Therefore, it is recommended to buy ERAS.
- StrongBuy: 5
- Buy: 3
- Hold: 0
- Sell: 0
- StrongSell: 0
| Analysts Target Price | 20.3 | 44.9% |
P/B = 10.9212
Revenue TTM = 0.0 USD
EBIT TTM = -131.8m USD
EBITDA TTM = -128.7m USD
Long Term Debt = 40.7m USD (estimated: total debt 46.0m - short term 5.25m)
Short Term Debt = 5.25m USD (from shortTermDebt, last quarter)
Debt = 46.0m USD (from shortLongTermDebtTotal, last quarter) (leases 46.0m already included)
Net Debt = -197.8m USD (calculated: Debt 46.0m - CCE 243.8m)
Enterprise Value = 3.99b USD (4.19b + Debt 46.0m - CCE 243.8m)
Interest Coverage Ratio = -0.91 (Ebit TTM -131.8m / Interest Expense TTM 145.3m)
EV/FCF = -16.14x (Enterprise Value 3.99b / FCF TTM -247.4m)
FCF Yield = -6.20% (FCF TTM -247.4m / Enterprise Value 3.99b)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 3.11m) / Revenue TTM)
Tobins Q-Ratio = 8.66 (Enterprise Value 3.99b / Total Assets 461.2m)
Interest Expense / Debt = 316.1% (Interest Expense 145.3m / Debt 46.0m)
Taxrate = 21.0% (US federal default 21%)
NOPAT = -104.1m (EBIT -131.8m * (1 - 21.00%)) [loss with tax shield]
Current Ratio = 8.80 (Total Current Assets 253.8m / Total Current Liabilities 28.8m)
Debt / Equity = 0.12 (Debt 46.0m / totalStockholderEquity, last quarter 393.5m)
Debt / EBITDA = 1.54 (negative EBITDA) (Net Debt -197.8m / EBITDA -128.7m)
Debt / FCF = 0.80 (negative FCF - burning cash) (Net Debt -197.8m / FCF TTM -247.4m)
Total Stockholder Equity = 359.7m (last 4 quarters mean from totalStockholderEquity)
RoA = -59.42% (Net Income -277.0m / Total Assets 461.2m)
RoE = -77.01% (Net Income TTM -277.0m / Total Stockholder Equity 359.7m)
RoCE = -32.90% (EBIT -131.8m / Capital Employed (Equity 359.7m + L.T.Debt 40.7m))
RoIC = -23.67% (negative operating profit) (NOPAT -104.1m / Invested Capital 439.8m)
WACC = 12.26% (E(4.19b)/V(4.24b) * Re(12.39%) + (debt cost/tax rate unavailable))
Discount Rate = 12.39% (= CAPM, Blume Beta Adj.)
Shares (quarterly) Correlation: 95.56 | Cagr: 50.90%
[DCF] Fair Price = unknown (Cash Flow -247.4m)
EPS Correlation: N/A | EPS CAGR: N/A | SUE: -4.0 | # QB: -1
Revenue Correlation: N/A | Revenue CAGR: N/A | SUE: 0.0 | # QB: 0
EPS current Quarter (2026-06-30): EPS=-0.12 | Chg30d=-7.84% | Revisions=-33% | Analysts=8
EPS next Quarter (2026-09-30): EPS=-0.12 | Chg30d=-8.62% | Revisions=-43% | Analysts=8
EPS current Year (2026-12-31): EPS=-0.97 | Chg30d=-70.11% | Revisions=-64% | GrowthEPS=-119.5% | GrowthRev=+0.0%
EPS next Year (2027-12-31): EPS=-0.56 | Chg30d=-4.16% | Revisions=-33% | GrowthEPS=+41.6% | GrowthRev=+0.0%
[Analyst] Revisions Ratio: -64%